Page 46 - Demo

44 CPD ACTIVITY FROM PAGE 43 A large, retrospective review’. Dermatologic Therapy, 2017 Jul; 30 (4): e12483. 48. Van TN, Thi LD, Trong HN, Van TC, Minh TT, Minh PP, Huu ND, Cam VT, Le Huyen M, Hau KT, Gandolfi M. ‘Efficacy of oral isotretinoin in combination with desloratadine in the treatment of common vulgaris acne in Vietnamese patients’. Open access Macedonian Journal of Medical Sciences, 2019 Jan 30; 7 (2): 217. 49. Dhaher SA, Jasim ZM. ‘The adjunctive effect of desloratadine on the combined azithromycin and isotretinoin in the treatment of severe acne: Randomised clinical trial’. Journal of Dermatology and Dermatologic Surgery, 2018 Jan 1; 22 (1) :21. 50. Lee HE, Chang IK, Lee Y, Kim CD, Seo YJ, Lee JH, Im M. ‘Effect of antihistamine as an adjuvant treatment of isotretinoin in acne: A randomised, controlled comparative study’. Journal of the European Academy of Dermatology and Venereology, 2014 Dec; 28 (12): 1654-60. 51. Ruiz-Lozano RE, Hernández-Camarena JC, Garza-Garza LA, Bustamante-Arias A, Colorado-Zavala MF, Cardenas-de la Garza JA. ‘Isotretinoin and the eye: A review for the dermatologist’. Dermatologic Therapy, 2020 Jul 19: e14029. 52. Wong RC, Gilbert M, Woo TY, Kang S, Petersen C, Ellis CN. ‘Photosensitivity and isotretinoin therapy’. Journal of the American Academy of Dermatology, 1986 Jun; 14 (6): 1095-6. 53. Ramot Y, Zlotogorski A. ‘Wax stripping and isotretinoin treatment: A warning not to be missed’. Department of Dermatology, Hadassah Medical Centre, Faculty of Medicine, Hebrew University of Jerusalem, Israel. 54. Colburn WA, Gibson DM, Wiens RE, Hanigan JJ. ‘Food increases the bioavailability of isotretinoin’. The Journal of Clinical Pharmacology, 1983 Nov 12; 23 (11): 534-9. 55. Roche Products Pty Ltd. Roaccutane (isotretinoin). Australian Product Information \[Internet\]. Available from: ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/ pdf?OpenAgent&id=CP-2010-PI-01746-3&d=202104261016933 Accreditation Number: A2106RP1 (exp: 31/05/2023) This activity has been accredited for 1 hour of Group One CPD (or 1 CPD credit) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 1 hour of Group Two CPD (or 2 CPD credits) upon successful completion of relevant assessment activities. 1. Which of the following statements regarding the pathophysiology of acne is INCORRECT? A) Hyperproliferation of keratinocytes leads to obstruction of a follicle. B) Increasedsebumproductionisstimulatedbythepresenceofandrogens. C) Follicular colonisation by Cutibacterium acnes within the sebum occurs. D) Acne is recognised as a chronic infectious disease. 2. Which of the following statements is FALSE? A) Topical retinoids can be used for acne that is more predominantly affected by comedones. B) Topical antibiotics are preferred for acne presenting with more inflammation. C) The benzoyl peroxide 5 per cent cream is more useful than the wash for treating acne over large surface areas such as the back and chest. D) Most patients should initiate treatment with benzoyl peroxide 5 per cent rather than the 2.5 per cent. 3. Which of the following three statements (i-iii) are considered contraindications for treatment with Isotretinoin? i) Family history of depression. ii) Current diagnosis of depression. iii) Pregnancy. A) i, ii, iii. B) iii, ii. C) iii, i. D) iii. 4. Which of the following is the most common adverse effect from oral isotretinoin treatment? A) Depression. B) Dry eye disease. C) Photosensitivity. D) Dry lips. 5. Which of the following counselling points regarding isotretinoin treatment is FALSE? A) Patients should ensure they take isotretinoin with a meal. B) Patients should not wax their skin for at least six hours after taking isotretinoin. C) Patients should avoid any supplement with vitamin A. D) Isotretinoin should usually be continued for at least one month after the symptoms resolve. among Singaporean students in tertiary institutions’. JDDG, 2015 Mar; 13 (3): 227-33. 15. Das S, Reynolds RV. ‘Recent advances in acne pathogenesis: implications for therapy. American Journal of Clinical Dermatology, 2014 Dec; 15 (6): 479-88. 16. Fitz-Gibbon S, Tomida S, Chiu B-H, Nguyen L, Du C, Liu M, et al. ‘Propionibacterium acnes strain populations in the human skin microbiome associated with acne’. J Invest Dermatol, 2013 Sep; 133 (9): 2152-60. 17. See JA. ‘Drug treatment of acne’. Australian Prescriber, 2012; 35 (6): 74–8. 18. Ramanathan S, Hebert AA. ‘Management of acne vulgaris’. Journal of Pediatric Health Care, 2011 Sep 1; 25 (5): 332. 19. Australian Medicines Handbook. Adelaide: Australian Medicines Handbook Pty Ltd; 2020. 20. Cunliffe WJ, Holland KT. ‘The effect of benzoyl peroxide on acne’. Acta dermatovenereologica, 1981 Jan 1; 61 (3): 267-9. 21. Fakhouri T, Yentzer BA, Feldman SR. ‘Advancement in benzoyl peroxide-based acne treatment: Methods to increase both efficacy and tolerability’. Journal of Drugs in Dermatology (JDD), 2009 Jul 1; 8 (7): 657-61. 22. Sagransky M, Yentzer BA, Feldman SR. ‘Benzoyl peroxide: A review of its current use in the treatment of acne vulgaris’. Expert Opinion on Pharmacotherapy, 2009 Oct 1; 10 (15): 2555-62. 23. Walsh TR, Efthimiou J, Dréno B. ‘Systematic review of antibiotic resistance in acne: An increasing topical and oral threat’. The Lancet Infectious Diseases, 2016 Mar 1; 16 (3): e23-33. 24. Panchaud A, Csajka C, Merlob P, Schaefer C, Berlin M, De Santis M, Vial T, Ieri A, Malm H, Eleftheriou G, Stahl B. ‘Pregnancy outcome following exposure to topical retinoids: A multicentre prospective study’. The Journal of Clinical Pharmacology, 2012 Dec; 52 (12): 1844-51. 25. Kaplan YC, Ozsarfati J, Etwel F, Nickel C, Nulman I, Koren G. ‘Pregnancy outcomes following first‐trimester exposure to topical retinoids: A systematic review and meta‐ analysis’. British Journal of Dermatology, 2015 Nov; 173 (5): 1132-41. 26. Khalil S, Bardawil T, Stephan C, Darwiche N, Abbas O, Kibbi AG, Nemer G, Kurban M. ‘Retinoids: A journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects’. Journal of Dermatological Treatment, 2017 Nov 17; 28 (8): 684-96. 27. Yentzer BA, McClain RW, Feldman SR. ‘Do topical retinoids cause acne to ‘flare’?’JDD, 2009 Sep; 8 (9): 799-801. 28. Cooper AJ, Harris VR. ‘Modern management of acne’. The Medical Journal of Australia, 2017 Jan 1; 206 (1): 41-5. 29. Layton A. ‘The use of isotretinoin in acne’. Dermato-endocrinology, 2009 May 1; 1 (3): 162-9. 30. Bauer LB, Ornelas JN, Elston DM, Alikhan A. ‘Isotretinoin: Controversies, facts, and recommendations’. Expert Review of Clinical Pharmacology, 2016 Nov 1; 9 (11): 1435-42. 31. Vasicek B, Adams W, Steadman L, Reserva J, Swan J. ‘Coprescription of isotretinoin and systemic corticosteroids for acne: An analysis of the national ambulatory medical care survey.’ The Journal of Clinical and Aesthetic Dermatology, 2019 Jun; 12 (6): 27. 32. RACGP, Position Statement. ‘GP Prescribing rights for Isotretinoin’ \[Internet\], 2014 May. Available from: racgp.org.au/download/Documents/Reports/ racgpisotretinoinsubmission.pdf 33. Poisons Standard, February 2021. \[Federal Register of Legislation\] \[internet\]. February 2021 \[cited 24/4/21\]. Available from: legislation.gov.au/Details/ F2021C00098 34. Pharmaceutical Management Agency. ‘Changes to prescriber restrictions for acitretin and isotretinoin approved’. PHARMAC, 2008. Available from: pharmac.health.nz 35. Rademaker M. ‘Making sense of the effects of the cumulative dose of isotretinoin in acne vulgaris’. International Journal of Dermatology, 2016 May; 55 (5): 518-23. 36. Landis MN. ‘Optimising isotretinoin treatment of acne: Update on current recommendations for monitoring, dosing, safety, adverse effects, compliance, and outcomes’. American Journal of Clinical Dermatology, 2020 Jun; 21 (3): 411-9. 37. Tran PT, Berman HS, Leavitt E, Hogeling M, Cheng CE. ‘Analysis of factors associated with relapse in patients on their second course of isotretinoin for acne vulgaris’. Journal of the American Academy of Dermatology, 2021 Mar 1; 84 (3): 856-9. 38. Vallerand IA, Lewinson RT, Farris MS, Sibley CD, Ramien ML, Bulloch AG, Patten SB. ‘Efficacy and adverse events of oral isotretinoin for acne: A systematic review’. British Journal of Dermatology, 2018 Jan; 178 (1): 76-85. 39. Poisons Standard, February 2021. \[Federal Register of Legislation\] \[Internet\]. February 2021 \[cited 24/4/21\]. Available from: legislation.gov.au/Details/ F2021C00098 40. Halvorsen JA, Stern RS, Dalgard F, Thoresen M, Bjertness E, Lien L. ‘Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: A population-based study’. Journal of Investigative Dermatology, 2011 Feb 1; 131 (2): 363-70. 41. Oliveira JM, Sobreira G, Velosa J, Telles Correia D, Filipe P. ‘Association of isotretinoin with depression and suicide: A review of current literature’. Journal of Cutaneous Medicine and Surgery, 2018 Jan; 22 (1): 58-64. 42. Atallahb RB, Abo Alwafa HO, El Mahdy MA, Mahmoud AE. ‘A prospective study of the risk of depression in acne patients treated with oral isotretinoin’. The Egyptian Journal of Hospital Medicine, 2019 Jan 1; 74 (1): 142-6. 43. Erdoğan Y, Erturan İ, Aktepe E, Akyıldız A. ‘Comparison of quality of life, depression, anxiety, suicide, social anxiety and obsessive–compulsive symptoms between adolescents with acne receiving isotretinoin and antibiotics: A prospective, non- randomised, open-label study’. Pediatric Drugs, 2019 Jun; 21 (3): 195-202. 44. Bray AP, Kravvas G, Skevington SM, Lovell CR. ‘Is there an association between isotretinoin therapy and adverse mood changes? A prospective study in a cohort of acne patients’. Journal of Dermatological Treatment, 2019 Nov 17; 30 (8): 796-801. 45. Huang YC, Cheng YC. ‘Isotretinoin treatment for acne and risk of depression: A systematic review and meta-analysis’. Journal of the American Academy of Dermatology, 2017 Jun 1; 76 (6): 1068-76. 46. Affleck A, Stewart M, Nicolson J, Salmon N. ‘Isotretinoin and mental health: A survey of Scottish Dermatology Society members. Clinical and Experimental Dermatology, 2019 Nov 15. 47. Brzezinski P, Borowska K, Chiriac A, Smigielski J. ‘Adverse effects of isotretinoin: RETAIL PHARMACY • JUN 2021 An overview of severe acne treatment 2 CPD CREDITS